Skip to main content
SpringerLink
Log in

Immunopathology of Head and Neck Tumors and Immunotherapy of Squamous Cell Carcinoma

  • Chapter
Cancer Immunology

  • 2896 Accesses

Abstract

The competent immune system controls disease effectively due to induction, function, and regulation of effector lymphocytes. Although immunosurveillance has been induced by cytotoxic T lymphocytes (CTLs), specific immune suppression is associated with tumor malignancy and progression. This contributes to unsatisfactory clinical outcome. In squamous cell carcinoma of the head and neck, the presence, activity, and also suppression of tumor-specific CTL have been demonstrated. Another important tumor-escape mechanism is to avoid recognition by dysregulation of antigen processing and presentation. Thus, both induction of functional CTL and susceptibility of the tumor and its microenvironment to become T cell targets should be considered in CTL-based immunotherapy. Recently, immunotherapy has been challenged by the cancer stem(-like) cells (CSCs) paradigm. These cells show resistance to current treatment options and are held responsible for the initiation, metastasis, and recurrence of the disease. Thus, investigations on the interaction of CSCs with the host immune system have been performed, and targeting CSCs will potentially result in improved therapeutic outcome in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22.

    Article  CAS  PubMed  Google Scholar 

  2. Bottley G, Watherston OG, Hiew YL, Norrild B, Cook GP, Blair GE. High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene. 2008;27(12):1794–9.

    Article  CAS  PubMed  Google Scholar 

  3. Guirat-Dhouib N, Baccar Y, Mustapha IB, Ouederni M, Chouaibi S, El Fekih N, et al. Oral HPV infection and MHC class II deficiency (a study of two cases with atypical outcome). Clin Mol Allergy. 2012;10(1):6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S. Immune suppression in head and neck cancers: a review. Clin Dev Immunol. 2010;2010:701657.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother. 2005;54(3):187–207.

    Article  CAS  PubMed  Google Scholar 

  6. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909–15.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Schaefer C, Butterfield LH, Lee S, Kim GG, Visus C, Albers A, et al. Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int J Cancer. 2012;131(4):874–84.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother. 2005;54(11):1072–81.

    Article  CAS  PubMed  Google Scholar 

  10. Albers AE, Schaefer C, Visus C, Gooding W, DeLeo AB, Whiteside TL. Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer. Head Neck. 2009;31(6):773–81.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res. 2005;65(23):11146–55.

    Article  CAS  PubMed  Google Scholar 

  12. Albers AE, Visus C, Tsukishiro T, Ferris RL, Gooding W, Whiteside TL, et al. Alterations in the T-cell receptor variable beta gene-restricted profile of CD8+ T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2006;12(8):2394–403.

    Article  CAS  PubMed  Google Scholar 

  13. Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8(8):2553–62.

    PubMed  Google Scholar 

  14. Chikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, et al. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res. 2003;63(13):3675–81.

    CAS  PubMed  Google Scholar 

  15. Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther. 2012;12(10):1383–97.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Lanzavecchia A, Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol. 2002;2(12):982–7.

    Article  CAS  PubMed  Google Scholar 

  17. Czystowska M, Gooding W, Szczepanski MJ, Lopez-Abaitero A, Ferris RL, Johnson JT, et al. The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. Clin Cancer Res. 2013;19(4):889–99.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Watanabe M, Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Maruyama T, et al. Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2010;102(3):520–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL, et al. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res. 1999;5(6):1281–8.

    CAS  PubMed  Google Scholar 

  20. Soussi T. The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol Today. 1996;17(8):354–6.

    Article  CAS  PubMed  Google Scholar 

  21. Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, et al. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol. 2000;165(10):5938–44.

    Article  CAS  PubMed  Google Scholar 

  22. Schaefer C, Kim GG, Albers A, Hoermann K, Myers EN, Whiteside TL. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer. 2005;92(5):913–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163(10):5211–8.

    CAS  PubMed  Google Scholar 

  24. Kuss I, Donnenberg AD, Gooding W, Whiteside TL. Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. Br J Cancer. 2003;88(2):223–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998;188(12):2357–68.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005;54(8):721–8.

    Article  CAS  PubMed  Google Scholar 

  27. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 2001;22(5):269–76.

    Article  PubMed  Google Scholar 

  28. Chikamatsu K, Sakakura K, Yamamoto T, Furuya N, Whiteside TL, Masuyama K. CD4+ T helper responses in squamous cell carcinoma of the head and neck. Oral Oncol. 2008;44(9):870–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Ito D, Albers A, Zhao YX, Visus C, Appella E, Whiteside TL, et al. The wild-type sequence (wt) p53(25-35) peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ Th cells capable of enhancing the ex vivo expansion and function of anti-wt p53(264-272) peptide CD8+ T cells. J Immunol. 2006;177(10):6795–803.

    Article  CAS  PubMed  Google Scholar 

  30. Chikamatsu K, Sakakura K, Takahashi G, Okamoto A, Furuya N, Whiteside TL, et al. CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer. Cancer Immunol Immunother. 2009;58(9):1441–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Bhat P, Mattarollo SR, Gosmann C, Frazer IH, Leggatt GR. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev. 2011;239(1):85–98.

    Article  CAS  PubMed  Google Scholar 

  32. Hoffmann TK, Loftus DJ, Nakano K, Maeurer MJ, Chikamatsu K, Appella E, et al. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. J Immunol. 2002;168(3):1338–47.

    Article  CAS  PubMed  Google Scholar 

  33. Williams R, Lee DW, Elzey BD, Anderson ME, Hostager BS, Lee JH. Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck. 2009;31(7):911–8.

    Article  PubMed  Google Scholar 

  34. Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol. 2002;12(1):43–50.

    Article  CAS  PubMed  Google Scholar 

  35. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10(11):3755–62.

    Article  CAS  PubMed  Google Scholar 

  36. Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL. Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv Otorhinolaryngol. 2005;62:161–72.

    CAS  PubMed  Google Scholar 

  37. Tsukishiro T, Donnenberg AD, Whiteside TL. Rapid turnover of the CD8(+)CD28(−) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother. 2003;52(10):599–607.

    Article  PubMed  Google Scholar 

  38. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res. 2002;8(10):3137–45.

    PubMed  Google Scholar 

  39. Strauss L, Bergmann C, Whiteside TL. Human circulating CD4+ CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol. 2009;182(3):1469–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother. 1999;48(7):346–52.

    Article  CAS  PubMed  Google Scholar 

  41. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998;58(23):5344–7.

    CAS  PubMed  Google Scholar 

  42. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res. 2000;6(9):3560–4.

    CAS  PubMed  Google Scholar 

  43. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6(11):1142–51.

    Article  CAS  PubMed  Google Scholar 

  44. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169(5):2756–61.

    Article  CAS  PubMed  Google Scholar 

  45. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13(21):6301–11.

    Article  CAS  PubMed  Google Scholar 

  46. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007;13(15 Pt 1):4345–54.

    Article  CAS  PubMed  Google Scholar 

  47. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–9.

    Article  CAS  PubMed  Google Scholar 

  48. Boucek J, Mrkvan T, Chovanec M, Kuchar M, Betka J, Boucek V, et al. Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck. J Cell Mol Med. 2010;14(1–2):426–33.

    Article  CAS  PubMed  Google Scholar 

  49. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006;12(2):465–72.

    Article  CAS  PubMed  Google Scholar 

  50. Loose D, Signore A, Bonanno E, Vermeersch H, Dierckx R, Deron P, et al. Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous-cell carcinoma of the head and neck. Cancer Biother Radiopharm. 2008;23(1):25–33.

    Article  CAS  PubMed  Google Scholar 

  51. Alhamarneh O, Amarnath SM, Stafford ND, Greenman J. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer? Head Neck. 2008;30(2):251–61.

    Article  PubMed  Google Scholar 

  52. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol. 2002;32(11):3267–75.

    Article  CAS  PubMed  Google Scholar 

  53. Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2002;2:1.

    PubMed  Google Scholar 

  54. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol. 2006;177(1):84–91.

    Article  CAS  PubMed  Google Scholar 

  55. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother. 2012;61(3):353–62.

    Article  CAS  PubMed  Google Scholar 

  56. Gritzapis AD, Voutsas IF, Baxevanis CN. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice. Cancer Immunol Immunother. 2012;61(3):397–407.

    Article  CAS  PubMed  Google Scholar 

  57. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007;110(9):3192–201.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194(6):823–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12(13):3890–5.

    Article  CAS  PubMed  Google Scholar 

  60. Wang S, Chen L. T lymphocyte co-signaling pathways of the B7-CD28 family. Cell Mol Immunol. 2004;1(1):37–42.

    PubMed  Google Scholar 

  61. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181–273.

    Article  CAS  PubMed  Google Scholar 

  62. Vambutas A, DeVoti J, Pinn W, Steinberg BM, Bonagura VR. Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin Immunol. 2001;101(1):94–9.

    Article  CAS  PubMed  Google Scholar 

  63. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991–8.

    Article  CAS  PubMed  Google Scholar 

  64. Albers AE, Kaufmann AM. Therapeutic human papillomavirus vaccination. Public Health Genomics. 2009;12(5–6):331–42.

    Article  PubMed  Google Scholar 

  65. Hoffmann TK, Arsov C, Schirlau K, Bas M, Friebe-Hoffmann U, Klussmann JP, et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer. 2006;118(8):1984–91.

    Article  CAS  PubMed  Google Scholar 

  66. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol. 2001;19(6):1211–20.

    CAS  PubMed  Google Scholar 

  67. DeLeo AB, Whiteside TL. Development of multi-epitope vaccines targeting wild-type sequence p53 peptides. Expert Rev Vaccines. 2008;7(7):1031–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Sakakura K, Chikamatsu K, Furuya N, Appella E, Whiteside TL, Deleo AB. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides. Clin Immunol. 2007;125(1):43–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans. 2013;41(1):245–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  70. Baskic D, Vujanovic L, Arsenijevic N, Whiteside TL, Myers EN, Vujanovic NL. Suppression of natural killer-cell and dendritic-cell apoptotic tumoricidal activity in patients with head and neck cancer. Head Neck. 2013;35(3):388–98.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Whiteside TL. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther. 2010;10(7):1019–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today. 2000;21(9):455–64.

    Article  CAS  PubMed  Google Scholar 

  73. Whiteside TL. Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother. 2012;61(2):283–8.

    Article  CAS  PubMed  Google Scholar 

  74. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011;33(4):369–83.

    Article  CAS  PubMed  Google Scholar 

  75. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  76. Chikamatsu K, Sakakura K, Toyoda M, Takahashi K, Yamamoto T, Masuyama K. Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck. Cancer Sci. 2012;103(6):976–83.

    Article  CAS  PubMed  Google Scholar 

  77. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052–61.

    Article  CAS  PubMed  Google Scholar 

  78. Chen C, Wei Y, Hummel M, Hoffmann TK, Gross M, Kaufmann AM, et al. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One. 2011;6(1):e16466.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Qian X, Wagner S, Ma C, Klussmann JP, Hummel M, Kaufmann AM, et al. ALDH1-positive cancer stem-like cells are enriched in nodal metastases of oropharyngeal squamous cell carcinoma independent of HPV status. Oncol Rep. 2013;29(5):1777–84.

    CAS  PubMed  Google Scholar 

  80. Chen YC, Chang CJ, Hsu HS, Chen YW, Tai LK, Tseng LM, et al. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol. 2010;46(3):158–65.

    Article  CAS  PubMed  Google Scholar 

  81. Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009;385(3):307–13.

    Article  CAS  PubMed  Google Scholar 

  82. Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, et al. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res. 2007;67(21):10538–45.

    Article  CAS  PubMed  Google Scholar 

  83. Kiessling A, Schmitz M, Stevanovic S, Weigle B, Holig K, Fussel M, et al. Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer. 2002;102(4):390–7.

    Article  CAS  PubMed  Google Scholar 

  84. Xu Q, Liu G, Yuan X, Xu M, Wang H, Ji J, et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells. 2009;27(8):1734–40.

    Article  CAS  PubMed  Google Scholar 

  85. Garcia-Hernandez Mde L, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 2008;68(3):861–9.

    Article  CAS  PubMed  Google Scholar 

  86. Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-Merino B, et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res. 2006;66(21):10247–52.

    Article  CAS  PubMed  Google Scholar 

  87. Dhodapkar MV. Immunity to stemness genes in human cancer. Curr Opin Immunol. 2010;22(2):245–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  88. Liao T, Kaufmann AM, Qian X, Sangvatanakul V, Chen C, Kube T, et al. Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines. J Cancer Res Clin Oncol. 2013;139(1):159–70.

    Article  CAS  PubMed  Google Scholar 

  89. Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012;72(7):1853–64.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  90. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743–53.

    Article  CAS  PubMed  Google Scholar 

  91. Nikitina EY, Clark JI, Van Beynen J, Chada S, Virmani AK, Carbone DP, et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res. 2001;7(1):127–35.

    CAS  PubMed  Google Scholar 

  92. Azuma K, Shichijo S, Maeda Y, Nakatsura T, Nonaka Y, Fujii T, et al. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res. 2003;63(4):854–8.

    CAS  PubMed  Google Scholar 

  93. Molling JW, Moreno M, de Groot J, van der Vliet HJ, von Blomberg BM, van den Eertwegh AJ, et al. Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases. Immunol Lett. 2008;118(1):36–43.

    Article  CAS  PubMed  Google Scholar 

  94. Shibuya TY, Wei WZ, Zormeier M, Ensley J, Sakr W, Mathog RH, et al. Anti-CD3/anti-CD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2000;126(4):473–9.

    Article  CAS  PubMed  Google Scholar 

  95. Visus C, Wang Y, Lozano-Leon A, Ferris RL, Silver S, Szczepanski MJ, et al. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8(+) T cells. Clin Cancer Res. 2011;17(19):6174–84.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  96. Victora GD, Socorro-Silva A, Volsi EC, Abdallah K, Lima FD, Smith RB, et al. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther. 2009;16(7):598–608.

    Article  CAS  PubMed  Google Scholar 

  97. Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 2012;72(5):1116–25.

    Article  CAS  PubMed  Google Scholar 

  98. Seixas-Silva Jr JA, Richards T, Khuri FR, Wieand HS, Kim E, Murphy B, et al. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. Arch Otolaryngol Head Neck Surg. 2005;131(4):304–7.

    Article  PubMed  Google Scholar 

  99. van Herpen CM, van der Voort R, van der Laak JA, Klasen IS, de Graaf AO, van Kempen LC, et al. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int J Cancer. 2008;123(10):2354–61.

    Article  CAS  PubMed  Google Scholar 

  100. De Stefani A, Forni G, Ragona R, Cavallo G, Bussi M, Usai A, et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer. 2002;95(1):90–7.

    Article  PubMed  Google Scholar 

  101. To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P, et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg. 2000;126(10):1225–31.

    Article  CAS  PubMed  Google Scholar 

  102. Freeman SM, Franco JL, Kenady DE, Baltzer L, Roth Z, Brandwein HJ, et al. A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2011;34(2):173–8.

    CAS  PubMed  Google Scholar 

  103. Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y, et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 2004;64(21):8057–61.

    Article  CAS  PubMed  Google Scholar 

  104. Kurosaki M, Horiguchi S, Yamasaki K, Uchida Y, Motohashi S, Nakayama T, et al. Migration and immunological reaction after the administration of alphaGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer. Cancer Immunol Immunother. 2011;60(2):207–15.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology and Head and Neck Surgery, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

    Xu Qian MD & Andreas E. Albers MD, PhD

  2. Department of Gynecology, Campus Benjamin Franklin and Campus Mitte, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

    Andreas M. Kaufmann PhD

Authors
  1. Xu Qian MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas M. Kaufmann PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andreas E. Albers MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas E. Albers MD, PhD .

Editor information

Editors and Affiliations

  1. Children's Medical Center, Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Qian, X., Kaufmann, A.M., Albers, A.E. (2015). Immunopathology of Head and Neck Tumors and Immunotherapy of Squamous Cell Carcinoma. In: Rezaei, N. (eds) Cancer Immunology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46410-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-46410-6_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-46409-0

  • Online ISBN: 978-3-662-46410-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation